Assenagon Asset Management S.A. Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

Assenagon Asset Management S.A. reduced its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 81.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,530 shares of the company's stock after selling 61,087 shares during the quarter. Assenagon Asset Management S.A.'s holdings in DaVita were worth $2,070,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Sanctuary Advisors LLC purchased a new stake in shares of DaVita in the 4th quarter worth about $180,000. CIBC Asset Management Inc raised its position in shares of DaVita by 1.4% in the 4th quarter. CIBC Asset Management Inc now owns 7,730 shares of the company's stock worth $1,156,000 after purchasing an additional 109 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in DaVita in the 4th quarter worth about $597,000. Finally, Kentucky Retirement Systems Insurance Trust Fund boosted its stake in DaVita by 357.7% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 6,252 shares of the company's stock worth $935,000 after purchasing an additional 4,886 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of DVA stock traded down $0.86 during mid-day trading on Wednesday, hitting $135.65. The company had a trading volume of 833,544 shares, compared to its average volume of 821,547. The company has a market capitalization of $10.24 billion, a P/E ratio of 14.49, a P/E/G ratio of 0.94 and a beta of 1.11. The stock's 50 day moving average price is $140.92 and its 200-day moving average price is $150.68. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.26 EPS. Equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analysts Set New Price Targets

DVA has been the subject of several analyst reports. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Truist Financial decreased their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.